Seventh International Colorectal Cancer Congress
Physicians' Education Resource
Last Modified: June 1, 2008
Conference Dates: October 16-18, 2008
Conference Location: Aventura, FL
Sponsoring Group: Physicians' Education Resource
Conference Web Page URL: http://www.cancerconferences.com/gastrointestinal/7th_ccc/index.php
Topics Covered: The Seventh International Colorectal Cancer Congress is dedicated to an in-depth discussion of the best care options for the comprehensive management of patients with colorectal cancer. A significant emphasis will be given to case-based clinical scenarios in order to provide a forum for discussion, and expert opinion leaders will debate current controversies on the application of emerging clinical trial findings to daily practice. The optimal integration of biologic agents, such as EGFR inhibitors, antiangiogenic agents, and other novel agents, into current chemotherapy regimens will be addressed. Multidisciplinary approaches to the treatment of rectal cancer will be discussed, including developments in radiation therapy, surgery, and chemotherapy treatments. Participants will also gain insight into the pharmacogenomics of colorectal cancer and how this knowledge will aid in the prediction and prognostication of treatment response. The goal of this congress is for participants to integrate the latest advances in the treatment of colorectal cancer into their daily practice as well as to discuss future directions in research and clinical trials.
At the conclusion of this conference, you should be able to: Describe the role of KRAS in patient selection for and predicting clinical outcome from EGFR-targeted therapy Discuss the use of molecular and diagnostic approaches to pharmacogenomic profiling in order to predict treatment response and toxicity Review biomarkers predictive of response to or toxicity with targeted and cytotoxic agents Explain optimal adjuvant therapy for early-stage colorectal cancer, including the validity of anti-VEGF antibody therapy Determine the optimal duration of adjuvant chemotherapy for colorectal cancer based on clinical evidence Describe the merits of surgery alone or in combination with neoadjuvant therapy for the initial management of uT3 rectal cancer Explain the optimal chemotherapy, neoadjuvant and adjuvant, for use in chemoradiation treatment strategies for rectal cancer Choose optimal therapy for patients with newly diagnosed metastatic disease Compare the efficacy and safety of oral and infusional fluoropyrimidines Discuss the pros and cons of intermittent versus continuous chemotherapy as treatment for advanced disease and discuss therapeutic strategies for maximizing patient benefit Determine the optimal dose of and appropriate duration of treatment with anti-VEGF antibodies, including in patients who have progressed during therapy, in the metastatic setting Discuss the utility of tyrosine kinase inhibitors in the treatment of advanced colorectal cancer Compare the utility of VEGFR- and EGFR-targeted agents as first-line therapy for metastatic disease Compare the individualized treatment strategies employed in North America and in Europe for the management of metastatic colorectal cancer Explain whether all patients with colorectal liver metastases should receive neoadjuvant chemotherapy until they achieve best response or resectability Evaluate optimal chemotherapy for use in the perioperative treatment setting for patients with metastatic colorectal cancer Review surgical advances in the resection of liver metastases that maximize curative chance Assess available management options for minimizing treatment-related adverse events associated with anti-EGFR monoclonal antibody therapies Discuss the management of adverse events such as hypertension, bleeding, and wound-healing complications associated with VEGF-targeted therapy based on their mechanisms of action Summarize clinical trial updates regarding EGFR-targeted therapy, as monotherapy or in combination regimens, as first-line therapy and in recurrent disease Evaluate emerging clinical data on new targeted agents in colorectal cancer
Who Should Attend: This educational program is directed toward medical, surgical, and radiation oncologists; colorectal surgeons; gastroenterologists; internal medicine and primary care physicians; basic researchers and investigators; practitioners; and fellows interested in colorectal cancer. Nurses, physician assistants, and other individuals interested in the treatment of colorectal cancer are also invited to attend.
Registration Information: Registration fees include continental breakfasts, lunches, and syllabus materials. * INDUSTRY is defined by PER as any person employed by a for-profit organization, including biotech, financial, and pharmaceutical. Industry registrations cannot be processed online. To request attendance at a meeting, registration can be submitted via fax, phone, or e-mail. For more information, e-mail us at CME@pergrouplp.com. † Prices reflect discount. A cancellation fee of 25% will be assessed on refunds requested prior to September 18, 2008, and a 50% cancellation fee will be applied to refunds requested between September 18, 2008, and October 2, 2008. No refunds will be made after October 2, 2008. There is no charge for substitution. An additional 3% charge will be deducted from all credit cards. Guest tickets for social events only: Adults: $25.00 Children 12 years of age and younger: $10.00
Conference Fees: Before July 1, 2008 Physicians $395.00, Fellows, Pharmacists, Nurses, Other $295.00, Industry* $2695.00 Prices increase July 1st 2008
Continuing Education: Yes, Physicians: Physicians’ Education Resource is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Physicians’ Education Resource designates this educational activity for a maximum of 17.25 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity. Physician Assistants: AAPA accepts category 1 credit from AOACCME, Prescribed credit from AAFP, and AMA Category 1 CME credit for the PRA from organizations accredited by the ACCME.